Loading
Intercept Pharmaceuticals, Inc. Stock: price and insider trades · United States
Intercept Pharmaceuticals, Inc.: what insiders have been doing
Intercept Pharmaceuticals, Inc., founded in 2002, is a Healthcare & Pharma company based in New York City, United States. Its directors and officers file their transactions with SEC (Form 4). The past year has been quiet: not a single insider filing for Intercept Pharmaceuticals, Inc. The previous disclosure was published on 13 November 2023.
Since 2016, the database holds no purchases and 10 sales by insiders of the company.
In the same sector, recent insider purchases at Anixa Biosciences Inc and Vivos Inc also feature in our signals. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
149
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
10 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2022FY ended December 2022 · cache
Income statement
RevenueUS$246M
Net incomeUS$191M77.6% margin
Last declaration on 13 November 2023
Declarations149 total
15,038 shares@ US$19.0084.7% of flowCommon StockSEC:0001104659-23-117100:0
23,548 shares@ US$19.00100.0% of flowCommon StockSEC:0001104659-23-117097:0
25,487 shares@ US$19.00100.0% of flowCommon StockSEC:0001104659-23-117110:0
22,304 shares@ US$19.00100.0% of flowCommon StockSEC:0001104659-23-117105:0
24,719 shares@ US$19.00100.0% of flowCommon StockSEC:0001104659-23-117102:0
16,706 shares@ US$19.0077.5% of flowCommon StockSEC:0001104659-23-117112:0
14,766 shares@ US$19.00100.0% of flowCommon StockSEC:0001104659-23-117104:0
618,894 shares@ US$19.0093.9% of flowCommon StockSEC:0001104659-23-117094:0
51,815 shares@ US$19.0084.3% of flowCommon StockSEC:0001104659-23-117096:0
22,681 shares@ US$19.0072.7% of flowCommon StockSEC:0001104659-23-117099:0
28,349 shares@ US$19.0076.9% of flowCommon StockSEC:0001104659-23-117115:0
23,447 shares@ US$19.00100.0% of flowCommon StockSEC:0001104659-23-117109:0
23,645 shares@ US$19.00100.0% of flowCommon StockSEC:0001104659-23-117106:0
10,782 shares@ US$19.0086.2% of flowCommon StockSEC:0001104659-23-117117:0
23,021 shares@ US$19.0079.2% of flowCommon StockSEC:0001104659-23-117093:0
35,794 shares@ US$19.00100.0% of flowCommon StockSEC:0001104659-23-117113:0
37,887 shares@ US$19.00100.0% of flowCommon StockSEC:0001104659-23-117119:0
771 shares@ US$18.962.5% of flowCommon StockSEC:0001104659-23-114267:0
908 shares@ US$10.801.8% of flowCommon StockSEC:0001104659-23-103508:0
1,246 shares@ US$11.572.1% of flowCommon StockSEC:0001104659-23-101573:0
771 shares@ US$10.501.3% of flowCommon StockSEC:0001104659-23-087247:0
908 shares@ US$11.741.9% of flowCommon StockSEC:0001104659-23-074233:0
1,246 shares@ US$12.042.1% of flowCommon StockSEC:0001104659-23-072210:0
8,111 shares0Common StockSEC:0001104659-23-064844:0
8,111 shares0Common StockSEC:0001104659-23-064846:0
25 of 149 declarations
About Intercept Pharmaceuticals, Inc.
Intercept Pharmaceuticals, Inc. is a U.S.-based biopharmaceutical company focused on rare and serious liver diseases. The company is listed on the NASDAQ market under the ticker ICPT and is headquartered in Morristown, New Jersey, in the United States. Founded in 2002, Intercept built its identity around the research, development, and commercialization of therapies aimed at high-unmet-need conditions in hepatology. The company’s public materials also emphasize its entrepreneurial origins, noting that it started as a vision in its founder’s small New York City apartment. ([interceptpharma.com](https://www.interceptpharma.com/?utm_source=openai))
Intercept’s business model has historically been centered on liver-disease franchises, especially primary biliary cholangitis (PBC), alongside broader work in rare and severe hepatic conditions such as severe alcohol-associated hepatitis (sAH). Its flagship commercial asset was Ocaliva (obeticholic acid), a farnesoid X receptor, or FXR, agonist developed for PBC. The company’s scientific narrative has been closely tied to FXR biology, which it describes as a core research platform with potential therapeutic application across multiple liver diseases. In practical terms, Intercept has been a highly specialized hepatology company rather than a diversified broad-based pharma player. ([interceptpharma.com](https://www.interceptpharma.com/?utm_source=openai))
Read moreShow less
From a competitive standpoint, Intercept carved out a niche in a small but medically important market with significant unmet need. That specialization gave it clinical and regulatory visibility, but it also meant a heavy dependence on a limited number of assets. Ocaliva became the company’s principal marketed product for years, making Intercept far more concentrated than large-cap peers. The company also reshaped its geographic footprint when it completed the transfer of ex-U.S. commercialization rights for Ocaliva to Advanz Pharma in 2022, effectively narrowing its commercial footprint and simplifying its international operating structure. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001270073/000110465922076890/tm2220300d1_ex99-1.htm?utm_source=openai))
The most important recent development is the voluntary withdrawal of OCALIVA from the U.S. market, effective November 14, 2025, according to Intercept. That action materially changes the company’s revenue profile and marks a major strategic inflection point, as the historical core asset has exited the market. Intercept also notes that certain portfolio assets are now owned by its parent company Alfasigma S.p.A., reflecting the post-merger ownership structure announced in 2023. For investors, ICPT should therefore be viewed as a U.S. specialty biotech with a strong scientific legacy, a narrow therapeutic focus, and a business profile that has been substantially redefined by the recent withdrawal of its lead product. ([interceptpharma.com](https://www.interceptpharma.com/uploads/2025/11/Intercept%20Pharmaceuticals%20Statement%20Regarding%20Withdrawal%20of%20OCALIVA%20From%20the%20US%20Market.pdf?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
